Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

SENS Research Foundation cuts ties with Aubrey de Grey

By Brian Buntz | August 23, 2021

SENS Research FoundationDr. Aubrey de Grey was once known for claiming that aging could be ‘cured’ in coming decades.

Now, the nonprofit SENS Research Foundation (Mountain View, Calif.) he co-founded in 2009 has fired him amidst a sexual harassment probe. The organization, which aimed to pioneer a field known as “rejuvenation biotechnology,” was concerned that de Grey would impede its investigation of the allegations of Celine Halioua, the CEO of veterinary biotech Loyal (San Francisco) and Laura Deming, a partner at the Longevity Fund (San Francisco).

In a statement, SENS noted that it had learned that Dr. de Grey was “indirectly attempting to apply pressure on one of the investigation’s participants.”

Deming accused de Grey of writing her an email when she was 17 that boasted of having “an ‘adventurous love life.’”

Halioua reported that de Grey encouraged her to use sexual tactics to entice donors to contribute to the SENS Research Foundation.

De Grey has denied the allegations, stating on Facebook that he had been “set up.”

Aubrey de Grey

Aubrey de Grey image courtesy of Wikipedia

He also said in a separate message that Celine Halioua’s “career is absolutely over as things stand, and the only reason it actually isn’t is because I am a man of honour who refuses to let somebody (especially a meteoric rising star) be burned at the stake while an actual [villain] gets away scot free and is thereby emboldened.”

The SENS Research Foundation initiated a third-party investigation of the allegations of Halioua and Deming in June. The investigation is ongoing.

On Facebook, De Grey stated that he could form a new foundation, “proceeding as if nothing had happened,” but that he prefers to “get the truth known, my foundation back, and the bad actors excised from our community,” he wrote.

SENS Research Foundation has installed Lisa Fabiny-Kiser as acting executive director. Fabiny-Kiser was previously the organization’s vice president of operations.

SENS is an acronym for “Strategies for Engineered Negligible Senescence.”


Filed Under: Drug Discovery
Tagged With: Aubrey de Grey, rejuvenation biotechnology, SENS Research Foundation
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE